New hope for chinese patients with severe muscle weakness: eculizumab shows promise
NCT ID NCT06764160
First seen Jan 03, 2026 · Last updated May 23, 2026 · Updated 27 times
Summary
This study tested the drug eculizumab in 15 Chinese patients with refractory generalized myasthenia gravis (gMG), a condition causing severe muscle weakness that doesn't respond well to standard treatments. The goal was to see if eculizumab could improve daily activities and muscle strength over 26 weeks. Results help assess the drug's effectiveness and safety in this specific population.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENERALIZED MYASTHENIA GRAVIS (GMG) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Research Site
Changchun, 130021, China
-
Research Site
Fuzhou, 350001, China
-
Research Site
Guangzhou, 510080, China
-
Research Site
Guangzhou, 510620, China
-
Research Site
Qingdao, 266035, China
-
Research Site
Shanghai, 200040, China
Conditions
Explore the condition pages connected to this study.